Geovax Labs (Geovax Labs) 3-Year Dividend Growth Rate : 0.00% (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Geovax Labs 3-Year Dividend Growth Rate?

Geovax Labs's Dividends per Share for the three months ended in Mar. 2024 was $0.00.

The historical rank and industry rank for Geovax Labs's 3-Year Dividend Growth Rate or its related term are showing as below:

GOVXW's 3-Year Dividend Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 14.15
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Geovax Labs's Dividend Payout Ratio for the three months ended in Mar. 2024 was 0.00. As of today, Geovax Labs's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Geovax Labs's 3-Year Dividend Growth Rate

For the Biotechnology subindustry, Geovax Labs's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Geovax Labs's 3-Year Dividend Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Geovax Labs's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Geovax Labs's 3-Year Dividend Growth Rate falls into.

Geovax Labs 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Geovax Labs (NAS:GOVXW) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Geovax Labs's Dividend Payout Ratio for the quarter that ended in Mar. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Mar. 2024 )	/	EPS without NRI (Q: Mar. 2024 )
	=	0	/	0
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Geovax Labs 3-Year Dividend Growth Rate Related Terms>

Geovax Labs (Geovax Labs) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Geovax Labs Inc (NAS:GOVXW) » Definitions » 3-Year Dividend Growth Rate

Comparable Companies

Traded in Other Exchanges

GOVX:USA E8L:Germany

Address

1900 Lake Park Drive, Suite 380, Smyrna, GA, USA, 30080

Website

https://www.geovax.com

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.